Market Outlook
The global Blood Plasma Fractionation market size was valued at USD 29140 million in 2022 and is forecast to a readjusted size of USD 47720 million by 2029 with a CAGR of 7.3% during review period.
Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called Blood Plasma Fractionation.
Global key blood plasma fractionation players include CSL, Grifols and Takeda etc. The top 3 companies hold a share about 55%. North America is the largest market with a share about 40%, followed by Asia-Pacific and Europe. In terms of product, Immune Globulin is the largest segment with a share about 50%. And in terms of applications, the largest application is hospital with a share about 70%.
This report is a detailed and comprehensive analysis for global Blood Plasma Fractionation market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Blood Plasma Fractionation market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Blood Plasma Fractionation market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Blood Plasma Fractionation market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Blood Plasma Fractionation market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Blood Plasma Fractionation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Blood Plasma Fractionation market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segmentation By Type
Immune Globulin
Coagulation Factor
Albumin
Other
Segmentation By Application
Hospital
Retail Pharmacy
Other
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the blood plasma fractionation market in 2025?
The blood plasma fractionation market benefits from advanced technologies that improve efficiency and yield. Growing awareness of plasma-derived therapies for various diseases, such as immunodeficiencies and hemophilia, enhances market demand. Additionally, strong regulatory support for plasma collection and processing ensures quality and safety standards, bolstering consumer trust.
What are the weaknesses of the blood plasma fractionation market in 2025?
High costs associated with the fractionation process and the need for specialized facilities can limit market entry for new players. Additionally, reliance on voluntary blood donations can lead to supply fluctuations, impacting the availability of plasma for fractionation. Furthermore, the complexity of regulatory compliance may pose challenges for smaller organizations.
What are the opportunities in the blood plasma fractionation market in 2025?
The market has significant growth potential due to increasing prevalence of chronic diseases and the expanding use of immunoglobulin therapies. There is also an opportunity for innovation in product development, such as new plasma-derived therapies and improved fractionation techniques. Strategic partnerships and collaborations can enhance market reach and resource sharing.
What are the threats to the blood plasma fractionation market in 2025?
Emerging competitors and alternative therapies, such as synthetic products, pose a threat to traditional plasma fractionation. Economic fluctuations and changes in healthcare policies may impact funding and reimbursement for plasma therapies. Additionally, any negative publicity related to blood donations or transfusions could diminish public trust and affect supply.
Market PESTEL Analysis
What are the political factors affecting the blood plasma fractionation market in 2025?
Government regulations on plasma collection, storage, and fractionation play a crucial role in market dynamics. Policies related to blood donation, ethical considerations, and international trade agreements impact supply chains and market expansion. Additionally, government funding for research and healthcare reimbursement policies can influence industry growth.
What are the economic factors influencing the market?
The rising cost of plasma fractionation, coupled with high R&D expenses, affects pricing and profitability. Economic stability and healthcare budgets determine the affordability of plasma-derived therapies. Currency fluctuations and global trade conditions also impact the cost of raw materials and supply chain logistics.
What social factors impact the market?
Growing awareness of plasma-derived therapies and their role in treating rare diseases drives market demand. However, social concerns about blood donation safety and ethical sourcing of plasma can influence donor participation. Additionally, an aging population with increasing chronic disease prevalence boosts the need for plasma-based treatments.
What technological factors shape the market?
Advancements in fractionation techniques enhance yield, efficiency, and purity of plasma products. Automation and AI-driven quality control systems improve safety and regulatory compliance. Innovations in recombinant alternatives may pose competition to traditional plasma-derived therapies.
What environmental factors affect the industry?
Sustainability concerns related to waste disposal from plasma processing facilities are gaining attention. Energy-intensive fractionation processes contribute to environmental challenges, prompting a push for greener technologies. Additionally, climate change can impact blood donation rates and supply chain stability.
What legal factors influence the market?
Strict regulatory frameworks govern plasma collection, processing, and distribution to ensure safety and efficacy. Intellectual property laws and patent protection impact innovation and market competition. Additionally, evolving compliance requirements across different regions create challenges for global market players.
Market SIPOC Analysis
Who are the key suppliers in the blood plasma fractionation market in 2025?
Suppliers include blood donation centers, plasma collection organizations, and regulatory-compliant plasma banks. Additionally, manufacturers of specialized equipment, filtration systems, and reagents required for fractionation play a crucial role in the supply chain.
What are the main inputs required for plasma fractionation?
The primary input is human blood plasma, collected through voluntary or compensated donations. Other essential inputs include anticoagulants, purification chemicals, advanced fractionation equipment, and stringent regulatory protocols to ensure quality and safety.
What are the core processes involved in plasma fractionation?
The process includes plasma collection, testing, and cryopreservation, followed by fractionation through precipitation or chromatography. Further purification, viral inactivation, and quality control testing ensure the safety and efficacy of plasma-derived products before packaging and distribution.
Who are the key output recipients in the market?
Outputs include plasma-derived therapies such as immunoglobulins, albumin, and clotting factors, which are supplied to hospitals, specialty clinics, and research institutions. Pharmaceutical companies and government healthcare agencies also play a role in product distribution.
Who are the primary customers of plasma fractionation products?
Key customers include healthcare providers, hospitals, and specialty treatment centers managing patients with immunodeficiencies, hemophilia, and neurological disorders. Additionally, government health programs, research organizations, and pharmaceutical companies rely on plasma-derived products for therapeutic and investigational use.
Market Porter's Five Forces
How intense is the threat of new entrants in the blood plasma fractionation market in 2025?
The threat of new entrants is moderate. The high capital investment required for specialized fractionation equipment, regulatory compliance, and plasma collection infrastructure makes market entry challenging. However, the growing demand for plasma-derived therapies presents opportunities for new players, especially in regions with expanding healthcare infrastructure.
How strong is the bargaining power of suppliers in the blood plasma fractionation market?
The bargaining power of suppliers is moderate to high. Plasma collection centers hold significant power due to the limited availability of raw plasma, which is crucial for the fractionation process. Additionally, suppliers of specialized equipment and reagents that ensure quality control also influence pricing and market dynamics.
How strong is the bargaining power of buyers in the blood plasma fractionation market?
The bargaining power of buyers is moderate. Large healthcare providers, government agencies, and pharmaceutical companies can negotiate better terms due to their buying volume. However, the relatively high cost and specialized nature of plasma-derived therapies limit the power of individual buyers, as they have few alternatives.
What is the threat of substitute products in the blood plasma fractionation market?
The threat of substitutes is moderate. While synthetic and recombinant alternatives to plasma-derived therapies are emerging, they are still in the early stages of development and have not yet replaced the need for plasma-based products in many therapeutic areas. However, advancements in biotechnology may pose a growing competitive threat in the future.
How competitive is the blood plasma fractionation market in 2025?
The market is highly competitive with a few dominant players, but it remains open to innovation. Established companies have strong brand recognition and regulatory expertise, while new entrants may offer differentiated products or services. Increased global demand for plasma therapies intensifies competition, particularly in emerging markets.
Market Upstream Analysis
What are the key upstream factors in the blood plasma fractionation market in 2025?
Key upstream factors include the availability of plasma donations, which depend on voluntary blood donations and donor recruitment strategies. Additionally, the development and supply of specialized fractionation equipment, reagents, and purification technologies are critical in ensuring the quality of plasma-derived products. Regulatory frameworks governing plasma collection and processing also play a vital role in the upstream supply chain.
How do suppliers and raw materials affect the market?
Suppliers of raw plasma, especially collection centers and plasma banks, directly impact the market. The quality and quantity of plasma available for fractionation are crucial in determining product yield and availability. The supply of reagents, chemicals, and advanced processing equipment is another key element, as any disruptions in the supply chain can affect production capacity and cost efficiency.
How does technology affect the upstream segment of the blood plasma fractionation market?
Advancements in technology, particularly in fractionation and purification processes, have a significant impact on upstream activities. Newer technologies enable higher yields, better quality control, and reduced operational costs. Additionally, innovations in automation, AI for quality testing, and virus inactivation methods improve upstream efficiency and regulatory compliance.
What are the regulatory challenges in the upstream segment?
Regulatory challenges are significant in the upstream segment due to strict guidelines surrounding plasma collection, donor safety, and product purity. Compliance with international and local regulations regarding blood safety, disease testing, and traceability of plasma is necessary, which can add complexity and cost to upstream operations.
How do market conditions affect upstream stakeholders?
Market conditions such as fluctuating demand for plasma-based therapies, economic downturns, or global health crises can impact upstream stakeholders. Plasma collection may face challenges during times of reduced public donations or health crises, while supply chain issues for reagents and equipment can arise from geopolitical or environmental factors.
Market Midstream Analysis
What are the key midstream activities in the blood plasma fractionation market in 2025?
Midstream activities in the plasma fractionation market primarily involve the processing, purification, and separation of plasma into various therapeutic components such as immunoglobulins, clotting factors, and albumin. This stage also includes quality control testing, viral inactivation, and storage, ensuring that the plasma-derived products meet safety and efficacy standards.
How do production and manufacturing processes impact the market?
The efficiency of production and manufacturing processes directly affects the market by determining the cost, yield, and quality of plasma-derived products. Optimized fractionation technologies and automated systems reduce operational costs, improve product consistency, and meet the growing global demand. Any inefficiencies or technological limitations can lead to increased costs and supply shortages.
What role do logistics and distribution play in midstream activities?
Logistics and distribution are crucial for ensuring the timely delivery of plasma-derived products to healthcare providers and pharmaceutical companies. The cold chain management required for the storage and transport of these products is critical to maintaining their quality. Delays or disruptions in logistics can lead to supply shortages and affect patient treatment outcomes.
How do regulatory and quality control factors affect midstream operations?
Regulatory compliance and stringent quality control measures are critical in midstream operations to ensure that plasma-derived products meet health and safety standards. The need for consistent product quality across batches, adherence to international guidelines, and regular inspections can add complexity and cost to midstream operations but are essential for ensuring market trust and patient safety.
How do market conditions influence midstream stakeholders?
Market conditions such as fluctuating demand for specific plasma-derived therapies or global health crises like pandemics can influence midstream stakeholders by either increasing production needs or leading to oversupply. Changes in pricing due to demand spikes or regulatory shifts can also impact the cost structure and profitability for companies involved in plasma fractionation and product manufacturing.
Market Downstream Analysis
What are the key downstream activities in the blood plasma fractionation market in 2025?
Downstream activities involve the distribution, marketing, and delivery of plasma-derived therapies to healthcare providers, pharmaceutical companies, and patients. This includes the packaging, labeling, and transport of finished products to hospitals, specialty clinics, and international markets, ensuring they reach the end-users safely and promptly.
How do market demand and customer needs influence downstream operations?
The demand for specific plasma-derived therapies, such as immunoglobulins and clotting factors, drives downstream operations. Shifts in patient populations, the emergence of new diseases, or increased awareness of plasma therapies influence the types of products in demand. The need for specialized treatments in regions with growing healthcare infrastructure further impacts distribution strategies.
What role do distribution channels play in the downstream segment?
Distribution channels, including direct sales, wholesalers, and third-party logistics providers, play a critical role in ensuring plasma-derived products reach healthcare providers in a timely manner. Effective distribution is essential for maintaining the cold chain and ensuring product quality. Expanding distribution networks in emerging markets also presents growth opportunities for downstream stakeholders.
How do regulatory requirements affect downstream operations?
Downstream operations are highly impacted by regulatory requirements surrounding the sale and distribution of plasma-derived products. These regulations ensure that products are safely handled, stored, and transported to maintain efficacy. Compliance with regional and international regulations, such as Good Distribution Practices (GDP), is necessary to avoid legal complications and ensure patient safety.
What are the challenges faced by downstream stakeholders in the market?
Downstream stakeholders face challenges related to supply chain disruptions, such as delays in transportation or storage issues due to cold chain requirements. The increasing demand for plasma-derived therapies also strains distribution networks, especially in regions with limited healthcare infrastructure. Additionally, evolving reimbursement policies and price pressures from insurers can affect profitability in the downstream segment.
Chapter 1, to describe Blood Plasma Fractionation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Blood Plasma Fractionation, with price, sales, revenue and global market share of Blood Plasma Fractionation from 2018 to 2023.
Chapter 3, the Blood Plasma Fractionation competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Blood Plasma Fractionation breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Blood Plasma Fractionation market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Blood Plasma Fractionation.
Chapter 14 and 15, to describe Blood Plasma Fractionation sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Blood Plasma Fractionation
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Blood Plasma Fractionation Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Immune Globulin
1.3.3 Coagulation Factor
1.3.4 Albumin
1.3.5 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Blood Plasma Fractionation Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Blood Plasma Fractionation Market Size & Forecast
1.5.1 Global Blood Plasma Fractionation Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Blood Plasma Fractionation Sales Quantity (2018-2029)
1.5.3 Global Blood Plasma Fractionation Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Blood Plasma Fractionation Product and Services
2.1.4 Takeda Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Takeda Recent Developments/Updates
2.2 CSL
2.2.1 CSL Details
2.2.2 CSL Major Business
2.2.3 CSL Blood Plasma Fractionation Product and Services
2.2.4 CSL Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 CSL Recent Developments/Updates
2.3 Grifols
2.3.1 Grifols Details
2.3.2 Grifols Major Business
2.3.3 Grifols Blood Plasma Fractionation Product and Services
2.3.4 Grifols Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Grifols Recent Developments/Updates
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Blood Plasma Fractionation Product and Services
2.4.4 Octapharma Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Octapharma Recent Developments/Updates
2.5 Kedrion
2.5.1 Kedrion Details
2.5.2 Kedrion Major Business
2.5.3 Kedrion Blood Plasma Fractionation Product and Services
2.5.4 Kedrion Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Kedrion Recent Developments/Updates
2.6 LFB Group
2.6.1 LFB Group Details
2.6.2 LFB Group Major Business
2.6.3 LFB Group Blood Plasma Fractionation Product and Services
2.6.4 LFB Group Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 LFB Group Recent Developments/Updates
2.7 Biotest
2.7.1 Biotest Details
2.7.2 Biotest Major Business
2.7.3 Biotest Blood Plasma Fractionation Product and Services
2.7.4 Biotest Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Biotest Recent Developments/Updates
2.8 BPL
2.8.1 BPL Details
2.8.2 BPL Major Business
2.8.3 BPL Blood Plasma Fractionation Product and Services
2.8.4 BPL Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 BPL Recent Developments/Updates
2.9 RAAS
2.9.1 RAAS Details
2.9.2 RAAS Major Business
2.9.3 RAAS Blood Plasma Fractionation Product and Services
2.9.4 RAAS Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 RAAS Recent Developments/Updates
2.10 CBPO
2.10.1 CBPO Details
2.10.2 CBPO Major Business
2.10.3 CBPO Blood Plasma Fractionation Product and Services
2.10.4 CBPO Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CBPO Recent Developments/Updates
2.11 Hualan Bio
2.11.1 Hualan Bio Details
2.11.2 Hualan Bio Major Business
2.11.3 Hualan Bio Blood Plasma Fractionation Product and Services
2.11.4 Hualan Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Hualan Bio Recent Developments/Updates
2.12 Tiantan Bio
2.12.1 Tiantan Bio Details
2.12.2 Tiantan Bio Major Business
2.12.3 Tiantan Bio Blood Plasma Fractionation Product and Services
2.12.4 Tiantan Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Tiantan Bio Recent Developments/Updates
2.13 Shuanglin Bio
2.13.1 Shuanglin Bio Details
2.13.2 Shuanglin Bio Major Business
2.13.3 Shuanglin Bio Blood Plasma Fractionation Product and Services
2.13.4 Shuanglin Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Shuanglin Bio Recent Developments/Updates
2.14 Boya Bio
2.14.1 Boya Bio Details
2.14.2 Boya Bio Major Business
2.14.3 Boya Bio Blood Plasma Fractionation Product and Services
2.14.4 Boya Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Boya Bio Recent Developments/Updates
2.15 Yuanda Shuyang
2.15.1 Yuanda Shuyang Details
2.15.2 Yuanda Shuyang Major Business
2.15.3 Yuanda Shuyang Blood Plasma Fractionation Product and Services
2.15.4 Yuanda Shuyang Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Yuanda Shuyang Recent Developments/Updates
2.16 Weiguang Bio
2.16.1 Weiguang Bio Details
2.16.2 Weiguang Bio Major Business
2.16.3 Weiguang Bio Blood Plasma Fractionation Product and Services
2.16.4 Weiguang Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Weiguang Bio Recent Developments/Updates
2.17 Nanyue Bio
2.17.1 Nanyue Bio Details
2.17.2 Nanyue Bio Major Business
2.17.3 Nanyue Bio Blood Plasma Fractionation Product and Services
2.17.4 Nanyue Bio Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Nanyue Bio Recent Developments/Updates
2.18 KM Biologics
2.18.1 KM Biologics Details
2.18.2 KM Biologics Major Business
2.18.3 KM Biologics Blood Plasma Fractionation Product and Services
2.18.4 KM Biologics Blood Plasma Fractionation Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 KM Biologics Recent Developments/Updates
3 Competitive Environment: Blood Plasma Fractionation by Manufacturer
3.1 Global Blood Plasma Fractionation Sales Quantity by Manufacturer (2018-2023)
3.2 Global Blood Plasma Fractionation Revenue by Manufacturer (2018-2023)
3.3 Global Blood Plasma Fractionation Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Blood Plasma Fractionation by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Blood Plasma Fractionation Manufacturer Market Share in 2022
3.4.2 Top 6 Blood Plasma Fractionation Manufacturer Market Share in 2022
3.5 Blood Plasma Fractionation Market: Overall Company Footprint Analysis
3.5.1 Blood Plasma Fractionation Market: Region Footprint
3.5.2 Blood Plasma Fractionation Market: Company Product Type Footprint
3.5.3 Blood Plasma Fractionation Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Blood Plasma Fractionation Market Size by Region
4.1.1 Global Blood Plasma Fractionation Sales Quantity by Region (2018-2029)
4.1.2 Global Blood Plasma Fractionation Consumption Value by Region (2018-2029)
4.1.3 Global Blood Plasma Fractionation Average Price by Region (2018-2029)
4.2 North America Blood Plasma Fractionation Consumption Value (2018-2029)
4.3 Europe Blood Plasma Fractionation Consumption Value (2018-2029)
4.4 Asia-Pacific Blood Plasma Fractionation Consumption Value (2018-2029)
4.5 South America Blood Plasma Fractionation Consumption Value (2018-2029)
4.6 Middle East and Africa Blood Plasma Fractionation Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
5.2 Global Blood Plasma Fractionation Consumption Value by Type (2018-2029)
5.3 Global Blood Plasma Fractionation Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
6.2 Global Blood Plasma Fractionation Consumption Value by Application (2018-2029)
6.3 Global Blood Plasma Fractionation Average Price by Application (2018-2029)
7 North America
7.1 North America Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
7.2 North America Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
7.3 North America Blood Plasma Fractionation Market Size by Country
7.3.1 North America Blood Plasma Fractionation Sales Quantity by Country (2018-2029)
7.3.2 North America Blood Plasma Fractionation Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
8.2 Europe Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
8.3 Europe Blood Plasma Fractionation Market Size by Country
8.3.1 Europe Blood Plasma Fractionation Sales Quantity by Country (2018-2029)
8.3.2 Europe Blood Plasma Fractionation Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Blood Plasma Fractionation Market Size by Region
9.3.1 Asia-Pacific Blood Plasma Fractionation Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Blood Plasma Fractionation Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
10.2 South America Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
10.3 South America Blood Plasma Fractionation Market Size by Country
10.3.1 South America Blood Plasma Fractionation Sales Quantity by Country (2018-2029)
10.3.2 South America Blood Plasma Fractionation Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Blood Plasma Fractionation Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Blood Plasma Fractionation Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Blood Plasma Fractionation Market Size by Country
11.3.1 Middle East & Africa Blood Plasma Fractionation Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Blood Plasma Fractionation Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Blood Plasma Fractionation Market Drivers
12.2 Blood Plasma Fractionation Market Restraints
12.3 Blood Plasma Fractionation Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Blood Plasma Fractionation and Key Manufacturers
13.2 Manufacturing Costs Percentage of Blood Plasma Fractionation
13.3 Blood Plasma Fractionation Production Process
13.4 Blood Plasma Fractionation Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Blood Plasma Fractionation Typical Distributors
14.3 Blood Plasma Fractionation Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Blood Plasma Fractionation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Blood Plasma Fractionation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Takeda Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Major Business
Table 5. Takeda Blood Plasma Fractionation Product and Services
Table 6. Takeda Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Takeda Recent Developments/Updates
Table 8. CSL Basic Information, Manufacturing Base and Competitors
Table 9. CSL Major Business
Table 10. CSL Blood Plasma Fractionation Product and Services
Table 11. CSL Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. CSL Recent Developments/Updates
Table 13. Grifols Basic Information, Manufacturing Base and Competitors
Table 14. Grifols Major Business
Table 15. Grifols Blood Plasma Fractionation Product and Services
Table 16. Grifols Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Grifols Recent Developments/Updates
Table 18. Octapharma Basic Information, Manufacturing Base and Competitors
Table 19. Octapharma Major Business
Table 20. Octapharma Blood Plasma Fractionation Product and Services
Table 21. Octapharma Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Octapharma Recent Developments/Updates
Table 23. Kedrion Basic Information, Manufacturing Base and Competitors
Table 24. Kedrion Major Business
Table 25. Kedrion Blood Plasma Fractionation Product and Services
Table 26. Kedrion Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Kedrion Recent Developments/Updates
Table 28. LFB Group Basic Information, Manufacturing Base and Competitors
Table 29. LFB Group Major Business
Table 30. LFB Group Blood Plasma Fractionation Product and Services
Table 31. LFB Group Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. LFB Group Recent Developments/Updates
Table 33. Biotest Basic Information, Manufacturing Base and Competitors
Table 34. Biotest Major Business
Table 35. Biotest Blood Plasma Fractionation Product and Services
Table 36. Biotest Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Biotest Recent Developments/Updates
Table 38. BPL Basic Information, Manufacturing Base and Competitors
Table 39. BPL Major Business
Table 40. BPL Blood Plasma Fractionation Product and Services
Table 41. BPL Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. BPL Recent Developments/Updates
Table 43. RAAS Basic Information, Manufacturing Base and Competitors
Table 44. RAAS Major Business
Table 45. RAAS Blood Plasma Fractionation Product and Services
Table 46. RAAS Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. RAAS Recent Developments/Updates
Table 48. CBPO Basic Information, Manufacturing Base and Competitors
Table 49. CBPO Major Business
Table 50. CBPO Blood Plasma Fractionation Product and Services
Table 51. CBPO Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. CBPO Recent Developments/Updates
Table 53. Hualan Bio Basic Information, Manufacturing Base and Competitors
Table 54. Hualan Bio Major Business
Table 55. Hualan Bio Blood Plasma Fractionation Product and Services
Table 56. Hualan Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Hualan Bio Recent Developments/Updates
Table 58. Tiantan Bio Basic Information, Manufacturing Base and Competitors
Table 59. Tiantan Bio Major Business
Table 60. Tiantan Bio Blood Plasma Fractionation Product and Services
Table 61. Tiantan Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Tiantan Bio Recent Developments/Updates
Table 63. Shuanglin Bio Basic Information, Manufacturing Base and Competitors
Table 64. Shuanglin Bio Major Business
Table 65. Shuanglin Bio Blood Plasma Fractionation Product and Services
Table 66. Shuanglin Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Shuanglin Bio Recent Developments/Updates
Table 68. Boya Bio Basic Information, Manufacturing Base and Competitors
Table 69. Boya Bio Major Business
Table 70. Boya Bio Blood Plasma Fractionation Product and Services
Table 71. Boya Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Boya Bio Recent Developments/Updates
Table 73. Yuanda Shuyang Basic Information, Manufacturing Base and Competitors
Table 74. Yuanda Shuyang Major Business
Table 75. Yuanda Shuyang Blood Plasma Fractionation Product and Services
Table 76. Yuanda Shuyang Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Yuanda Shuyang Recent Developments/Updates
Table 78. Weiguang Bio Basic Information, Manufacturing Base and Competitors
Table 79. Weiguang Bio Major Business
Table 80. Weiguang Bio Blood Plasma Fractionation Product and Services
Table 81. Weiguang Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. Weiguang Bio Recent Developments/Updates
Table 83. Nanyue Bio Basic Information, Manufacturing Base and Competitors
Table 84. Nanyue Bio Major Business
Table 85. Nanyue Bio Blood Plasma Fractionation Product and Services
Table 86. Nanyue Bio Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Nanyue Bio Recent Developments/Updates
Table 88. KM Biologics Basic Information, Manufacturing Base and Competitors
Table 89. KM Biologics Major Business
Table 90. KM Biologics Blood Plasma Fractionation Product and Services
Table 91. KM Biologics Blood Plasma Fractionation Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. KM Biologics Recent Developments/Updates
Table 93. Global Blood Plasma Fractionation Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 94. Global Blood Plasma Fractionation Revenue by Manufacturer (2018-2023) & (USD Million)
Table 95. Global Blood Plasma Fractionation Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 96. Market Position of Manufacturers in Blood Plasma Fractionation, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 97. Head Office and Blood Plasma Fractionation Production Site of Key Manufacturer
Table 98. Blood Plasma Fractionation Market: Company Product Type Footprint
Table 99. Blood Plasma Fractionation Market: Company Product Application Footprint
Table 100. Blood Plasma Fractionation New Market Entrants and Barriers to Market Entry
Table 101. Blood Plasma Fractionation Mergers, Acquisition, Agreements, and Collaborations
Table 102. Global Blood Plasma Fractionation Sales Quantity by Region (2018-2023) & (K Units)
Table 103. Global Blood Plasma Fractionation Sales Quantity by Region (2024-2029) & (K Units)
Table 104. Global Blood Plasma Fractionation Consumption Value by Region (2018-2023) & (USD Million)
Table 105. Global Blood Plasma Fractionation Consumption Value by Region (2024-2029) & (USD Million)
Table 106. Global Blood Plasma Fractionation Average Price by Region (2018-2023) & (US$/Unit)
Table 107. Global Blood Plasma Fractionation Average Price by Region (2024-2029) & (US$/Unit)
Table 108. Global Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Global Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Global Blood Plasma Fractionation Consumption Value by Type (2018-2023) & (USD Million)
Table 111. Global Blood Plasma Fractionation Consumption Value by Type (2024-2029) & (USD Million)
Table 112. Global Blood Plasma Fractionation Average Price by Type (2018-2023) & (US$/Unit)
Table 113. Global Blood Plasma Fractionation Average Price by Type (2024-2029) & (US$/Unit)
Table 114. Global Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Global Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Global Blood Plasma Fractionation Consumption Value by Application (2018-2023) & (USD Million)
Table 117. Global Blood Plasma Fractionation Consumption Value by Application (2024-2029) & (USD Million)
Table 118. Global Blood Plasma Fractionation Average Price by Application (2018-2023) & (US$/Unit)
Table 119. Global Blood Plasma Fractionation Average Price by Application (2024-2029) & (US$/Unit)
Table 120. North America Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 121. North America Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 122. North America Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 123. North America Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 124. North America Blood Plasma Fractionation Sales Quantity by Country (2018-2023) & (K Units)
Table 125. North America Blood Plasma Fractionation Sales Quantity by Country (2024-2029) & (K Units)
Table 126. North America Blood Plasma Fractionation Consumption Value by Country (2018-2023) & (USD Million)
Table 127. North America Blood Plasma Fractionation Consumption Value by Country (2024-2029) & (USD Million)
Table 128. Europe Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 129. Europe Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 130. Europe Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 131. Europe Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 132. Europe Blood Plasma Fractionation Sales Quantity by Country (2018-2023) & (K Units)
Table 133. Europe Blood Plasma Fractionation Sales Quantity by Country (2024-2029) & (K Units)
Table 134. Europe Blood Plasma Fractionation Consumption Value by Country (2018-2023) & (USD Million)
Table 135. Europe Blood Plasma Fractionation Consumption Value by Country (2024-2029) & (USD Million)
Table 136. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 137. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 138. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 139. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 140. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Region (2018-2023) & (K Units)
Table 141. Asia-Pacific Blood Plasma Fractionation Sales Quantity by Region (2024-2029) & (K Units)
Table 142. Asia-Pacific Blood Plasma Fractionation Consumption Value by Region (2018-2023) & (USD Million)
Table 143. Asia-Pacific Blood Plasma Fractionation Consumption Value by Region (2024-2029) & (USD Million)
Table 144. South America Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 145. South America Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 146. South America Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 147. South America Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 148. South America Blood Plasma Fractionation Sales Quantity by Country (2018-2023) & (K Units)
Table 149. South America Blood Plasma Fractionation Sales Quantity by Country (2024-2029) & (K Units)
Table 150. South America Blood Plasma Fractionation Consumption Value by Country (2018-2023) & (USD Million)
Table 151. South America Blood Plasma Fractionation Consumption Value by Country (2024-2029) & (USD Million)
Table 152. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Type (2018-2023) & (K Units)
Table 153. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Type (2024-2029) & (K Units)
Table 154. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Application (2018-2023) & (K Units)
Table 155. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Application (2024-2029) & (K Units)
Table 156. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Region (2018-2023) & (K Units)
Table 157. Middle East & Africa Blood Plasma Fractionation Sales Quantity by Region (2024-2029) & (K Units)
Table 158. Middle East & Africa Blood Plasma Fractionation Consumption Value by Region (2018-2023) & (USD Million)
Table 159. Middle East & Africa Blood Plasma Fractionation Consumption Value by Region (2024-2029) & (USD Million)
Table 160. Blood Plasma Fractionation Raw Material
Table 161. Key Manufacturers of Blood Plasma Fractionation Raw Materials
Table 162. Blood Plasma Fractionation Typical Distributors
Table 163. Blood Plasma Fractionation Typical Customers
List of Figures
Figure 1. Blood Plasma Fractionation Picture
Figure 2. Global Blood Plasma Fractionation Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Blood Plasma Fractionation Consumption Value Market Share by Type in 2022
Figure 4. Immune Globulin Examples
Figure 5. Coagulation Factor Examples
Figure 6. Albumin Examples
Figure 7. Other Examples
Figure 8. Global Blood Plasma Fractionation Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Blood Plasma Fractionation Consumption Value Market Share by Application in 2022
Figure 10. Hospital Examples
Figure 11. Retail Pharmacy Examples
Figure 12. Other Examples
Figure 13. Global Blood Plasma Fractionation Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Blood Plasma Fractionation Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Blood Plasma Fractionation Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Blood Plasma Fractionation Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Blood Plasma Fractionation Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Blood Plasma Fractionation Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Blood Plasma Fractionation by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Blood Plasma Fractionation Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Blood Plasma Fractionation Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Blood Plasma Fractionation Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Blood Plasma Fractionation Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Blood Plasma Fractionation Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Blood Plasma Fractionation Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Blood Plasma Fractionation Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Blood Plasma Fractionation Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Blood Plasma Fractionation Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Blood Plasma Fractionation Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Blood Plasma Fractionation Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Blood Plasma Fractionation Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Blood Plasma Fractionation Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Blood Plasma Fractionation Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Blood Plasma Fractionation Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Blood Plasma Fractionation Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Blood Plasma Fractionation Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Blood Plasma Fractionation Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Blood Plasma Fractionation Consumption Value Market Share by Region (2018-2029)
Figure 55. China Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Blood Plasma Fractionation Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Blood Plasma Fractionation Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Blood Plasma Fractionation Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Blood Plasma Fractionation Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Blood Plasma Fractionation Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Blood Plasma Fractionation Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Blood Plasma Fractionation Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Blood Plasma Fractionation Market Drivers
Figure 76. Blood Plasma Fractionation Market Restraints
Figure 77. Blood Plasma Fractionation Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Blood Plasma Fractionation in 2022
Figure 80. Manufacturing Process Analysis of Blood Plasma Fractionation
Figure 81. Blood Plasma Fractionation Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
